TVTX
Travere Therapeutics, Inc.
Biotechnology · Healthcare · United States
50.57
close · 2026-10-29
value
29
cheaper than peers29
quality
35
stronger fundamentals35
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 9.38× | 89 |
| price to sales | 10.88× | 53 |
| EV to EBITDA | 321.71× | 5 |
| price to book | 194.50× | 0 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -29.0% | 68 |
| revenue growth | 55.6% | 68 |
| return on equity | -69.4% | 35 |
| debt to equity | 331.9% | 8 |
4 of 4 measures available
Facts
| market cap | $5B |
| free cash flow | -$51.2M |
| employees | 497 |
| first trade | 2012-11-08 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.29 | -4.08 | -1.50 | -4.37 |
| free cash flow | -$20.4M | -$338.7M | -$321.6M | -$214.7M |
| net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M |
| revenue | $490.7M | $233.2M | $145.2M | $109.5M |
| unusual items | $0 | -$2.4M | -$11.4M | -$7.6M |